"We will draw upon the resources of the University to advance a national dialogue about the threats to the medical innovation process and to advances that can make a great difference in the lives of patients,” said Dr. Gulfo.
Madison, NJ (PRWEB) April 16, 2015
Fairleigh Dickinson University (FDU) has recruited Dr. Joseph V. Gulfo to become the Executive Director of the Rothman Institute of Innovation and Entrepreneurship. Simultaneously, FDU announced the kick-off of the Initiative for Patient Centered Innovation (iPCI), a new program spearheaded by Dr. Gulfo, under the Rothman Institute of Innovation and Entrepreneurship (within the Silberman College of Business) and in collaboration with FDU’s School of Pharmacy’s Center for Healthcare Innovation and Technology.
A serial entrepreneur and leader in biopharma, Gulfo is the author of Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances and a contributor to Inc.com. He has more than 25 years of experience in the pharmaceutical and medical device industries and received the American Business Awards Maverick of the Year Award in 2012. He also teaches graduate courses on strategic innovation management in FDU’s MBA program.
“Dr. Gulfo is an accomplished innovator, entrepreneur, manager and writer with a passion for teaching who will lead the Rothman Institute of Innovation and Entrepreneurship, focusing on the launch of the Institute’s healthcare-related initiatives,” said Dr. Christopher A. Capuano, University Provost and Senior Vice President for Academic Affairs.
“The Initiative for Patient-Centered Innovation (iPCI) will advance FDU as a center of excellence, knowledge, learning, and policy proposals that will help shape public policy that affects the way biopharmaceutical and related companies conduct business, particularly relating to patentable products and devices that lead to the advancement of science and medicine,” said Dr. Andrew J. Rosman, Dean of the Silberman College of Business.
Among the programs to be undertaken include the Medical Innovation Impact Index (MI3), Shadow Advisory Committee Panels (S-Panel AdComm), an Audit of Regulations and Guidance Documents relative to governing statutes. More details can be found here.
“We teach our students the skills and values required to provide patients with the appropriate innovations to help them live healthier and more productive lives. It is also important for us to advance the voice of patients about the nature and quality of the products and services available to promote their well-being,” said Dr. Michael J. Avaltroni, Dean of the University’s School of Pharmacy.
“FDU is in a unique place geographically (‘the world’s medicine cabinet’) and in its history to undertake this ambitious effort. We will draw upon the resources of the University to advance a national dialogue about the threats to the medical innovation process and to advances that can make a great difference in the lives of patients,” said Gulfo.
About Fairleigh Dickinson University
Devoted to the preparation of world citizens through global education, Fairleigh Dickinson is New Jersey's largest private university and features more than 100 liberal arts and professional degree programs, two international campuses, dozens of partnerships with internationally renowned institutions and special programs and status within the United Nations.